Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited, established in 1979, is a prominent Indian pharmaceutical company headquartered in Ahmedabad, Gujarat. The company specializes in the manufacturing and trading of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its diverse product portfolio spans 15 therapeutic categories, such as anti-infectives, respiratory treatments, gynecology, cardiology, central nervous system disorders, anti-diabetic, and anti-malarial medications.

In January 1995, Lincoln Pharmaceuticals transitioned from a partnership firm to a public limited company, with the Corporate Identification Number (CIN) L24230GJ1995PLC024288. The company is listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) under the ticker symbol "LINCOLN." As of March 13, 2026, Lincoln Pharmaceuticals reported a market capitalization of approximately ₹12.09 billion, with a revenue of ₹6.52 billion for the fiscal year ending March 2025.

The company employs over 1,700 individuals, reflecting its significant presence in the Indian pharmaceutical industry. Its manufacturing facilities are located in Khatraj and Mehsana, Gujarat, adhering to international quality standards. The official website for Lincoln Pharmaceuticals is www.lincolnpharma.com.

Lincoln Pharmaceuticals operates two state-of-the-art manufacturing facilities in Gujarat, India. The primary plant is situated in Khatraj, Mehsana district, and is certified by the European Union Good Manufacturing Practice (EU GMP), World Health Organization Good Manufacturing Practice (WHO GMP), and ISO 9001:2015. This facility specializes in producing a wide range of pharmaceutical formulations, including tablets, capsules, injectables, dry syrups, and ointments.

In 2021, Lincoln Pharmaceuticals expanded its production capabilities by acquiring a plant in Mehsana, Gujarat, to manufacture cephalosporin products. This facility is designed to meet the standards of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) and the European Union, and it has received WHO GMP certification. The Mehsana plant focuses on the production of tablets, capsules, dry syrups, and dry powder injections.

The leadership team at Lincoln Pharmaceuticals is headed by Managing Director Mahendra G. Patel, who has been instrumental in the company's growth and global expansion. Other key executives include Munjal M. Patel, Ashish R. Patel, Anand A. Patel, and Hasmukhbai I. Patel, who play pivotal roles in the company's strategic direction and operations.

Lincoln Pharmaceuticals has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Khatraj, Gujarat, has been certified by the European Union Good Manufacturing Practice (EU GMP) and the Therapeutic Goods Administration (TGA) of Australia, indicating compliance with stringent international quality standards.

In May 2020, the Khatraj facility received EU GMP certification from EudraGMP, and in October 2021, it obtained approval from Australia's TGA. These certifications enhance Lincoln Pharmaceuticals' ability to export its products to these regulated markets. The company has also been focusing on expanding its presence in the U.S. and U.K. markets, aiming to strengthen its global footprint.

Lincoln Pharmaceuticals has been actively expanding its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's manufacturing facilities are approved by over 60 countries' drug authorities, facilitating its entry into these regions. In 2016, Lincoln Pharmaceuticals entered regulated African and Latin American countries, marking a significant milestone in its global expansion strategy.

Lincoln Pharmaceuticals has strategically diversified its geographic presence to mitigate concentration risk and capitalize on growth opportunities across various regions. The company's exports span Europe, North and Latin America, Africa, Asia Pacific, and Southeast Asia, reflecting a well-balanced approach to market expansion. This diversification strategy enables Lincoln Pharmaceuticals to leverage different market dynamics and reduce dependency on any single region.

As of March 2026, Lincoln Pharmaceuticals has not publicly disclosed specific details regarding its FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The company's focus on obtaining certifications from other regulatory bodies, such as the EU GMP and TGA, suggests a strategic emphasis on markets where these approvals are critical. However, the absence of FDA-specific information may indicate limited direct engagement with the U.S. market or a strategic decision to prioritize other regions.

Lincoln Pharmaceuticals' manufacturing facility in Khatraj, Gujarat, has been certified by the World Health Organization Good Manufacturing Practice (WHO GMP) and the European Union Good Manufacturing Practice (EU GMP). These certifications demonstrate the company's commitment to maintaining high-quality manufacturing standards and facilitate its ability to export products to various international markets.

Lincoln Pharmaceuticals holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's facilities in Khatraj and Mehsana, Gujarat, comply with CDSCO regulations, ensuring adherence to national quality and safety standards. Additionally, Lincoln Pharmaceuticals has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), authorizing the export of its products to various international markets.

As of March 2026, there have been no publicly reported Form 483 observations, warning letters, or import alerts issued to Lincoln Pharmaceuticals by regulatory authorities. The company's adherence to international quality standards, as evidenced by certifications from EU GMP and TGA, suggests a proactive approach to regulatory compliance. However, the absence of detailed inspection histories may limit transparency regarding the company's interactions with certain regulatory bodies.

Lincoln Pharmaceuticals operates in a competitive landscape with several key players in the Indian pharmaceutical industry. Major competitors include Sun Pharmaceutical Industries, Torrent Pharmaceuticals, and Abbott India. While Lincoln Pharmaceuticals has a diverse product portfolio and a strong presence in various therapeutic areas, it faces competition from these larger entities, which may have more extensive resources and market reach. The company's focus on emerging markets and adherence to international quality standards provide avenues to differentiate itself and capture market share.

Lincoln Pharmaceuticals' key differentiators include its diverse product portfolio across 15 therapeutic categories, adherence to international quality standards with certifications from EU GMP and TGA, and a strategic focus on expanding into emerging markets. The company's manufacturing facilities in Gujarat, India, are designed to meet international standards, enhancing its competitiveness in the global market.

Lincoln Pharmaceuticals is strategically positioned as a manufacturer and trader of pharmaceutical products, with a focus on both domestic and international markets. The company's expansion into emerging markets and adherence to international quality standards indicate a strategic direction aimed at global growth. Future outlooks suggest continued emphasis on research and development, regulatory compliance, and market diversification to strengthen its position in the global pharmaceutical industry.

Lincoln Pharmaceuticals has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products, with a total export value of $78.7 million USD and 1,763 shipments across 40 products in 15 therapeutic categories. The company's adherence to international quality standards, as evidenced by certifications from EU GMP and TGA, indicates reliability and commitment to product quality. The strategic focus on emerging markets and compliance with regulatory requirements further underscores Lincoln Pharmaceuticals' reliability as a supplier.

Importers should verify the following certifications when considering Lincoln Pharmaceuticals as a supplier:

• EU GMP Certification: Confirms compliance with European Union Good Manufacturing Practice standards. Verification can be done through the European Medicines Agency (EMA) or the company's official website.

• TGA Approval: Indicates compliance with Australia's Therapeutic Goods Administration standards. Verification can be done through the TGA's official website or the company's official website.

• WHO GMP Certification: Demonstrates adherence to World Health Organization Good Manufacturing Practice standards. Verification can be done through the World Health Organization's official website or the company's official website.

When conducting due diligence on Lincoln Pharmaceuticals, consider the following steps:

• Verify